DHDaniela Huttner

Daniela Huttner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniela Huttner has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Retrospective analysis of adverse drug reaction enquiries to a hospital drug information service: lessons to be learned to increase in-hospital drug safety

    by Dorothea Strobach, Yvonne Pudritz, Daniela Huttner

    Objectives: Adverse drug reactions (ADRs) are a major drug safety concern and a frequent topic of enquiries to hospital drug information services. Our goal was to analyse these enquiries regarding background, complexity, nature of ADR, and involved drug classes to improve in-hospital drug safety. Methods: Retrospectively, ADR enquiries to a German university hospital pharmacy drug information 2018–2022 were analysed regarding enquirer (profession, medical specialty) and enquiry details (drugs, suspected ADR/enquiry prior to drug initiation, ADR system organ class, probable cause identified, and enquiry complexity). Key findings: Of 543 enquiries, 516 (95%) were asked by physicians, 493 (91%) patient-specific, 390 (71%) on suspected ADRs, and 153 (28%) prior to drug initiation. Enquiries originated frequently from internal medicine (74/13.6%), paediatrics (71/13.1%), neurology (70/12.9%), and haemato-oncology (62/11.4%). Most frequent ADRs were haematologic (94/17%) and hepatic (72/13%). The median number of drugs per enquiry was three (range 0–37), 209 (38%) enquiries referred to one specific drug, 165 (30%) concerned ≥11 drugs. A probable cause for suspected ADRs was identified in 75 (36%) enquiries concerning one drug and 155 (94%) with ≥11 drugs. Most frequent drugs were antineoplastic (54/25.8%), nervous-system-drugs (42/20.1%), and anti-infective (40/19.1%). Most enquiries (342/63%) were complex (multiple/specialist resources). Conclusions: Enquiries were usually asked by physicians referring to suspected ADRs in specific clinical situations. A probable cause was identified in many cases pointing to a direct positive impact on patient care. Enquiries prior to drug initiation should be encouraged to increase drug safety. Information on main ADR effects and drug classes helps with targeted counselling.


  • Posaconazole liquid vs tablet formulation in lung transplant recipients

    by D. Stelzer, A. Weber, F. Ihle, S. Matthes, F. Ceelen, G. Zimmermann, N. Kneidinger, R. Schramm, H. Winter, M. Zoller, et al.

    Summary: Posaconazole is an extended‐spectrum triazole antifungal used in the treatment and prophylaxis of Aspergillus infections. It is available as oral suspension (POS‐Liq) and delayed‐release tablets (POS‐Tab). The aim of this longitudinal, retrospective study was to compare the clinical effectiveness, toxicity and pharmacokinetics of POS‐Liq vs POS‐Tab in lung transplant recipients (LTx‐recipients), who were treated with both formulations subsequently. Twenty‐four consecutive LTx‐recipients with 191 documented posaconazole trough levels (PTLs) for POS‐Liq or POS‐Tab were included. The administered daily doses were 300 mg for POS‐Tab and 600 mg (prophylaxis) or 800 mg (therapy) for POS‐Liq. Target PTLs were ≥700 ng/mL (prophylaxis) and ≥1250 ng/mL (therapy). The overall prophylactic and therapeutic response rates were 78% and 67%, respectively. No cases of hepatotoxicity or QT‐prolongation were observed with either formulation. The achieved target PTLs were tripled under POS‐Tab compared to POS‐Liq with fewer risk factors for sub‐therapeutic PTLs. Concomitant administration of POS‐Tab significantly reduced the tacrolimus concentration‐to‐dose ratio (P = .001). We suggest the use of POS‐Tab is appropriate for prophylaxis and therapy of Aspergillus infections in LTx‐recipients, since POS‐Tab displayed more reliable PTLs with no added adverse events. However, we recommend regular drug monitoring for POS‐Liq and for therapy with POS‐Tab and that immunosuppressant levels are monitored closely when the posaconazole formulation is switched.